Chinese wolfberry-huang decoction traditional Chinese medicine as well as preparation method and application thereof
Through the polysaccharide molecules in the traditional Chinese medicine composition of Qihuangyin, the problem of difficulty in reducing blood sugar and blood lipids in patients with type 2 diabetes combined with hyperlipidemia is solved, and a safe and efficient treatment effect is achieved, suitable for long-term use and reduce the risk of side effects.
Patent Information
- Application Number
- CN202410968329.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, it is difficult to reduce blood sugar and blood lipids in patients with type 2 diabetes and treat hyperlipidemia at the same time, and long-term use of Western medicine has side effects, and there is a lack of safe and efficient drug solutions.
Using Qihuangyin Chinese medicine composition, including wolfberry, Pueraria root, Coix seed, Poria, yam and turmeric, polysaccharide molecules are extracted through steps such as pulverization, alcohol precipitation, protein deprotein, column chromatography, etc., to form hypoglycemia with medicine and food homologous hypoglycemia Regulate blood lipid ingredients.
Qihuangyin Chinese medicine effectively reduces the TC, TG and LDL-C levels in diabetes model rats, significantly reduces blood sugar and blood lipids, and is suitable for long-term use due to natural ingredients, which reduces the risk of side effects and improves the quality of life.
Smart Images

Figure CN119055737A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of natural medicines, and in particular to a Qihuangyin Chinese medicine and a preparation method and application thereof. Background Art
[0002] Hyperlipidemia refers to abnormal fat metabolism or operation that causes one or more lipids in plasma to be higher than normal. It is the primary cause of atherosclerosis and one of the important risk factors for cardiovascular disease. Studies have found that 40% of patients with type 2 diabetes have hyperlipidemia. Lowering blood lipid levels can delay the occurrence and development of macrovascular and microvascular complications of diabetes, and can delay or reverse the progression of atherosclerotic plaques, which is very important for diabetic patients to prevent coronary heart disease.
[0003] The causes of diabetes combined with hyperlipidemia are diverse and are related to diet, internal injuries, external infection, and physical constitution. Traditional Chinese medicine believes that this disease is a concurrent symptom of "dipsia". Most patients are obese people with overweight. Irregular diet damages the spleen and stomach, causing disordered transportation and transformation, endogenous dampness, accumulation of dampness and heat, fumigation of dampness and heat, and phlegm. Phlegm turbidity and fat accumulation.
[0004] Polysaccharides are polysaccharides composed of more than 10 monosaccharides connected by glycosidic bonds. They are an important type of primary metabolites of plants and are widely found in many edible plants such as Chinese herbal medicine, fruits, vegetables, fungi, algae, etc. Research in the past three decades has shown that polysaccharides have multiple biological activities such as lowering blood lipids, anti-oxidation, antibacterial, antiviral, regulating the immune system, anti-tumor, and lowering blood sugar, and have great application prospects in the fields of medicine and health food.
[0005] The clinical treatment of type 2 diabetes combined with dyslipidemia requires long-term medication. Currently, clinical hypoglycemic and lipid-lowering drugs are still mainly Western medicines. Although Western hypoglycemic and lipid-lowering drugs have definite clinical efficacy, they have a single target of action, and there is no Western medicine that can both lower blood sugar or lower blood lipids and is safe and effective. The clinical combination of the two will double the toxic and side effects, and long-term medication is difficult to achieve satisfactory results. Moreover, as the treatment course is prolonged, they will show side effects to varying degrees, which will affect the patient's physical and mental health and quality of life for a long time.
[0006] Therefore, it is necessary to propose a Chinese medicine composition that is both a medicine and a food and can lower blood sugar and regulate blood lipids and a preparation method thereof. Summary of the invention
[0007] The main purpose of the present invention is to provide a Chinese medicine Qihuangyin which is both a medicine and a food, and a preparation method and application thereof. The Chinese medicine Qihuangyin, unless otherwise specified, refers to a mixture of wolfberry, kudzu root, coix seed, yam, poria and turmeric as main ingredients. The Qihuangyin has a good effect of lowering blood sugar and regulating blood lipids.
[0008] In order to solve the above technical problems, the technical solution adopted by the present invention is: A Qihuangyin Chinese medicine comprises the following components in parts by weight: 10-30 parts of wolfberries, 10-30 parts of kudzu roots, 10-30 parts of coix seeds, 10-30 parts of tuckahoe, 10-30 parts of yam and 10-30 parts of turmeric.
[0009] Preferably, the Qihuangyin Chinese medicine comprises the following components in parts by weight: 20-30 parts of wolfberry, 18-24 parts of kudzu root, 15-19 parts of coix seed, 15-20 parts of poria, 10-14 parts of yam, and 10-15 parts of turmeric.
[0010] More preferably, the Qihuangyin Chinese medicine comprises the following components in parts by weight: 25 parts of wolfberry, 21 parts of kudzu root, 17 parts of coix seed, 15 parts of poria, 12 parts of yam, and 13 parts of turmeric.
[0011] Preferably, the preparation method of the Qihuangyin Chinese medicine comprises the following steps: weighing each component according to the formula, crushing, precipitating with ethanol, deproteinizing, washing, eluting by column chromatography, and dialyzing to obtain Qihuangyin polysaccharide molecules with the effects of lowering blood sugar and regulating blood lipids.
[0012] More preferably, the preparation method of the Qihuangyin Chinese medicine comprises the following steps: S1. Crushing: Weigh the formula amount of each component of Qihuangyin Chinese medicine, dry it, put it into a grinder, crush it and sieve it to obtain Qihuangyin powder; S2 alcohol precipitation: add ethanol to the Qihuangyin Chinese medicine powder in step S1 to an alcohol concentration of 75-85%, let stand for 45-50h, centrifuge to obtain a precipitate, dissolve in water, and freeze-dry to obtain a crude extract; S3. Repeated Sevage method to remove protein: add Sevage reagent to the crude extract of step S2, centrifuge and let stand, take the supernatant, repeat 3-5 times, then wash with anhydrous ethanol, acetone and ether in sequence, evaporate the solvent of the obtained precipitate, add water to re-dissolve, pre-freeze at -70°C, and then vacuum freeze-dry for 48 hours to obtain an extract; S4. Separation and purification by DEAE-52 chromatography column: The extract of step S3 is dissolved in ultrapure water, centrifuged, and then loaded onto a DEAE-52 chromatography column for elution, collected step by step, and the absorbance of the eluate is determined by the phenol-sulfuric acid method. An elution curve is drawn and an elution peak is obtained. The eluate of the elution peak is dialyzed and vacuum freeze-dried to obtain the Qihuangyin polysaccharide molecule.
[0013] Preferably, in step S1, the components of Qihuangyin are dried, put into a grinder, and crushed, and then passed through a 50-100 sieve to obtain Qihuangyin powder.
[0014] Preferably, in step S2, ethanol is added to the Qihuangyin powder of step S1 until the alcohol content is 80%, and the mixture is allowed to stand at 4°C for 48 hours.
[0015] Preferably, in step S3, anhydrous ethanol is centrifuged at 3500 rpm for 15 min, acetone is centrifuged at 3500 rpm for 15 min, and ether is centrifuged at 3500 rpm for 15 min.
[0016] Preferably, in step S3, the precipitate is re-dissolved in water, pre-frozen at -70°C for 2 hours, and then vacuum freeze-dried for 48 hours.
[0017] Preferably, in step S4, H2O, 0.2M, 0.4M and 0.6M NaCl solutions are respectively selected as eluents for elution, the elution volume for each concentration is 300ml, the flow rate is 1ml / min, the phenol-sulfuric acid method is used to detect and collect the active components, the eluates are combined according to the elution curve, and after concentration, the eluates are dialyzed and desalted for 48 hours with a molecular weight cutoff of 3000Da in a dialysis bag, and then the dialysate is concentrated and freeze-dried to obtain the Qihuangyin Chinese medicine polysaccharide molecule.
[0018] Preferably, infrared detection of the separated and purified substance in step S4 shows that at 3435.24 cm -1 The absorption peak at 2926.11 cm is the stretching vibration of OH in sugars. -1 The smaller absorption peak at 1400~1200cm is the stretching vibration of -CH3. -1 The peaks that appear may be CH angle vibrations of sugars. From the above, it can be determined that the sample is a polysaccharide. -1 The absorption peaks near 840 cm indicate that there may be pyranose ring structures in the polysaccharide. -1 The peaks near α indicate that the polysaccharide contains α-configuration, that is, has α-glycosidic bonds.
[0019] Preferably, the detection method of the polysaccharide molecules of the above-mentioned Qihuangyin Chinese medicine is: using GCMS to perform qualitative and quantitative analysis on the polysaccharide components of Qihuangyin, wherein the chromatographic column is DB-5MS (30m×0.25mm×0.25μm); the column temperature is maintained at 100°C for 5min, increased to 190°C at 20°C / min, increased to 260°C at 3°C / min, increased to 300°C at 10°C / min, and maintained for 10min; the injection temperature is 280°C; the injection volume is 1μL; the split ratio is 5:1; the carrier gas is helium (99.999%); the control mode is constant flow, 1.0ml / min; the interface temperature is 280°C; the ion source temperature is 230°C; the quadrupole temperature is 150°C; the ionization mode is EI+, 70ev; the detector voltage is 1471V; the scanning mode is full scan, 33~600, and the solvent delay is 5min; NIST2011 spectral library.
[0020] The present invention also provides a pharmaceutical composition, comprising the Qihuangyin Chinese medicine molecule and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is in the form of a granule, a capsule or a tablet.
[0021] The present invention also provides the use of the Qihuangyin Chinese medicine molecule in preparing medicines or health foods with the effects of lowering blood sugar and blood lipids.
[0022] The six traditional Chinese medicines of the present invention are all selected from the list of medicines and foods published by the National Health Commission, and are safe and have no toxic side effects. In the prescription, wolfberry nourishes yin and blood, improves essence and improves eyesight; kudzu root relieves muscles and reduces fever, promotes fluid production and quenches thirst, and is a monarch medicine. Coix seed promotes diuresis and reduces swelling, strengthens the spleen and removes dampness; Poria promotes diuresis and eliminates dampness, strengthens the spleen and calms the mind; yam nourishes the spleen and nourishes the stomach, promotes fluid production and benefits the lungs, and nourishes the kidney and astringes essence, and is a minister medicine. Turmeric promotes qi and removes blood stasis, promotes menstruation and relieves pain, and its warm nature can restrain the coldness of coix seed and kudzu root, and is an adjuvant. All the medicines are used together to play the role of nourishing yin, clearing heat and removing dampness.
[0023] Compared with the prior art, the present invention has the following beneficial effects: 1. The present invention obtains Qihuangyin polysaccharide molecules through crushing, alcohol precipitation, deproteinization, washing, column chromatography elution and dialysis; the extraction process of the present invention is short in time and can effectively preserve the activity of the polysaccharide molecules in Qihuangyin.
[0024] 2. The prescription of the Qihuang Decoction of the present invention is concise, the medicinal materials are easy to obtain, the cost of taking is low, and the therapeutic effect is definite, which can give full play to the advantages of simplicity, convenience, low cost and effectiveness of traditional Chinese medicine; the selected natural ingredients have mild medicinal properties and are more suitable for long-term use by patients with diabetes and hyperlipidemia.
[0025] 3. The Qihuangyin polysaccharide molecules of the present invention can significantly reduce the levels of TC, TG and LDL-C indicators in rats with glucose and lipid metabolism disorders, play a role in lowering blood sugar and regulating blood lipids, provide a basis for the development of health products and drugs for the treatment of type 2 diabetes, and have good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] The present invention will be further described below in conjunction with the accompanying drawings and embodiments: Figure 1 This is the infrared spectrum of the Qihuangyin Chinese medicine polysaccharide molecule obtained in Example 1 of the present invention; Figure 2 This is the HPGPC diagram of the Qihuangyin Chinese medicine polysaccharide molecule obtained in Example 1 of the present invention; Figure 3 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecules of Example 1 of the present invention on the activity of HepG2 cells; In the figure, polysaccharide is the polysaccharide molecule of Qihuangyin Chinese medicine; Figure 4The effect of the Qihuangyin Chinese medicine polysaccharide molecules in Example 1 of the present invention on the cells of the insulin resistance cell model; In the figure, control is the control group, DXMS is dexamethasone, Glucose is glucose, polysaccharide is the polysaccharide molecule of Qihuangyin Chinese medicine; L is low dose, M is medium dose; H is high dose; Figure 5 This is a diagram showing the effect of the Qihuangyin Chinese medicine polysaccharide molecules of Example 1 of the present invention on the intracellular ROS level; In the figure, control is the control group, DXMS is dexamethasone, Glucose is glucose, polysaccharide is the polysaccharide molecule of Qihuangyin Chinese medicine; M is the medium dose; Figure 6 This is a diagram showing the effect of the Qihuangyin Chinese medicine polysaccharide molecules of Example 1 of the present invention on the expression of cell proteins in an insulin resistance cell model; In the figure, DXMS is dexamethasone, Glucose is glucose, and polysaccharide is the polysaccharide molecule of Qihuangyin traditional Chinese medicine; Figure 7 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecules on rat liver in Example 1 of the present invention; Among them, Figure a is a staining picture of rat liver cells treated with the normal group; Figure b is a staining picture of rat liver cells treated with the model group; Figure c is a staining picture of rat liver cells treated with the metformin group; Figure d is a staining picture of rat liver cells treated with the atorvastatin calcium group; Figure e is a staining picture of rat liver cells treated with the low-dose group; Figure f is a staining picture of rat liver cells treated with the high-dose group; Figure 8 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecules on rat kidneys according to Example 1 of the present invention; Among them, Figure a is a staining picture of rat kidney cells treated with the normal group; Figure b is a staining picture of rat kidney cells treated with the model group; Figure c is a staining picture of rat kidney cells treated with the metformin group; Figure d is a staining picture of rat kidney cells treated with the atorvastatin calcium group; Figure e is a staining picture of rat kidney cells treated with the low-dose group; Figure f is a staining picture of rat kidney cells treated with the high-dose group; Fig. 9 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecule on the pancreas of rats according to Example 1 of the present invention; Among them, Figure a is a staining picture of pancreatic cells of rats treated with the normal group; Figure b is a staining picture of pancreatic cells of rats treated with the model group; Figure c is a staining picture of pancreatic cells of rats treated with the metformin group; Figure d is a staining picture of pancreatic cells of rats treated with the atorvastatin calcium group; Figure e is a staining picture of pancreatic cells of rats treated with the low-dose group; Figure f is a staining picture of pancreatic cells of rats treated with the high-dose group; Fig.10This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecular composition on FBG in patients with type 2 diabetes combined with hyperlipidemia according to Example 1 of the present invention; Fig.11 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecular composition on 2hPG in patients with type 2 diabetes combined with hyperlipidemia according to Example 1 of the present invention; Fig.12 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecular composition on HbA1c in patients with type 2 diabetes combined with hyperlipidemia according to Example 1 of the present invention; Fig.13 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecular composition on TC in patients with type 2 diabetes combined with hyperlipidemia according to Example 1 of the present invention; Fig.14 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecular composition on TG in patients with type 2 diabetes combined with hyperlipidemia according to Example 1 of the present invention; Fig.15 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecular composition on LDL-C in patients with type 2 diabetes combined with hyperlipidemia according to Example 1 of the present invention; Fig.16 This is a graph showing the effect of the Qihuangyin Chinese medicine polysaccharide molecular composition on HDL-C in patients with type 2 diabetes combined with hyperlipidemia according to Example 1 of the present invention; Fig.17 This is a graph showing the effect of the Qihuangyin Chinese medicinal polysaccharide molecular composition of Example 1 of the present invention on the total score of TCM symptoms in patients with type 2 diabetes combined with hyperlipidemia. DETAILED DESCRIPTION
[0027] Embodiment 1: A Qihuangyin Chinese medicine comprises the following components: 25 parts of wolfberries, 21 parts of kudzu roots, 17 parts of coix seeds, 15 parts of tuckahoe, 12 parts of yam and 13 parts of turmeric.
[0028] The preparation method of the Qihuangyin Chinese medicine comprises the following steps: S1. Crushing: Weigh the amount of each component of Qihuangyin Chinese medicine, dry it, put it into a grinder and grind it through 80 sieves to obtain Qihuangyin Chinese medicine powder; S2. Alcohol precipitation: add 4 times the volume of anhydrous ethanol to the Qihuangyin Chinese medicine powder in step S1 to an alcohol concentration of 80%, stand at 4 ° C for 48h, centrifuge to obtain a precipitate, dissolve in water, and freeze-dry to obtain a crude extract; S3. Repeated Sevage method to remove protein: add Sevage reagent to the crude extract of step S2, centrifuge at 3500rpm for 15min, let stand, take the supernatant, repeat 3-5 times, then centrifuge at 3500rpm for 15min with anhydrous ethanol, centrifuge at 3500rpm for 15min with acetone, centrifuge at 3500rpm for 15min with ether, then evaporate the solvent from the obtained precipitate, add water to re-dissolve, pre-freeze at -70℃ for 2h, and then vacuum freeze-dry for 48h to obtain the extract; S4. Separation and purification by DEAE-52 chromatography column: The extract of step S3 was dissolved in ultrapure water, centrifuged, and then loaded on a DEAE-52 chromatography column for elution. H2O, 0.2M, 0.4M and 0.6M NaCl solutions were selected as eluents, respectively. The elution volume for each concentration was 300ml, and the flow rate was 1ml / min. The active components were detected and collected by the phenol-sulfuric acid method. The eluates were combined according to the elution curve, concentrated, and dialyzed and desalted for 48 hours in a dialysis bag with a molecular weight cutoff of 3000Da. The dialysate was then concentrated and freeze-dried to obtain the Qihuangyin polysaccharide molecule.
[0029] Embodiment 2: A Qihuangyin Chinese medicine comprises the following components: 22 parts of wolfberries, 19 parts of kudzu roots, 16 parts of coix seeds, 12 parts of tuckahoe, 10 parts of yam and 11 parts of turmeric.
[0030] The preparation method is the same as Example 1.
[0031] Embodiment 3: A Qihuangyin Chinese medicine comprises the following components: 27 parts of wolfberries, 23 parts of kudzu roots, 17 parts of coix seeds, 16 parts of tuckahoe, 13 parts of yam and 14 parts of turmeric.
[0032] The preparation method is the same as Example 1.
[0033] Comparative Example 1: A Qihuangyin Chinese medicine comprises the following components: 25 parts of wolfberries, 21 parts of kudzu roots, 17 parts of coix seeds, 15 parts of tuckahoe, 12 parts of yam and 13 parts of turmeric.
[0034] The preparation method of the Qihuangyin Chinese medicine comprises the following steps: S1. Crushing: Weigh the amount of each component of Qihuangyin Chinese medicine, dry it, put it into a grinder and grind it through 80 sieves to obtain Qihuangyin powder; S2. Alcohol precipitation: add 4 times the volume of anhydrous ethanol to the Qihuangyin powder of step S1 to an alcohol concentration of 80%, stand at 4°C for 48 hours, centrifuge to obtain a precipitate, add water to dissolve it, and freeze-dry to obtain a crude extract.
[0035] Example 4 The structural analysis of the Qihuangyin Chinese medicine molecule in Example 1 was performed, and the results were as follows: 4.1 Chemical composition analysis: The chemical composition of the Qihuangyin Chinese medicine molecules was analyzed, and the results are shown in Table 1.
[0036] Table 1 Chemical composition of Qihuangyin polysaccharides
[0037] As shown in Table 1, the Qihuangyin Chinese medicine molecule of the present invention contains a small amount of uronic acid structure, with a content of 0.31±0.33%; the protein content is low, at 0.09±0.48%.
[0038] 4.2 Structural analysis: 4.2.1 Analysis of structural characteristics of crude polysaccharides using Fourier transform infrared spectrometer: Test conditions: Qihuangyin Chinese medicine molecular samples were taken, pressed into KBr tablets, and detected by Thermo Fisher Nicolet6700 FT-IR infrared spectrophotometer at 4000-500cm -1 Characteristic infrared absorption. The results are as follows Figure 1 shown.
[0039] from Figure 1 It can be seen that at 3435.24cm -1 The absorption peak at 2926.11 cm is the stretching vibration of OH in sugars. -1 The smaller absorption peak at 1400~1200cm is the stretching vibration of -CH3. -1 The peaks that appear may be CH angle vibrations of sugars. From the above, it can be determined that the sample is a polysaccharide. -1 The absorption peaks near 840 cm indicate that there may be pyranose ring structures in the polysaccharide. -1 The peaks near the α-glycosidic bonds indicate that the polysaccharide contains an α-configuration.
[0040] 4.2.2 HPGPC method was used to analyze the molecular weight of Qihuangyin Chinese medicine molecules: Test conditions: Aglient 1200 HPLC was used to detect the homogeneity and molecular weight of polysaccharides, the eluent was ultrapure water, the injection volume was 10 μl, the flow rate was 1 ml / min, the pressure was 35 Bar, the column temperature was 30 °C, and the detection wavelength was 215 nm. Figure 2 shown.
[0041] Depend on Figure 2 It can be seen that according to the peak time of the polysaccharide, the molecular mass (Mw) of the polysaccharide is calculated to be 2890.7 kDa.
[0042] Example 5 In vitro cell experiment: used to verify that the polysaccharide molecules of the Qihuangyin Chinese medicine of the present invention can intervene in the occurrence of diabetes and hyperlipidemia, and the specific steps are as follows: 5.1 Cell activity experiment: The CCK8 method was used to detect the effect of the Qihuangyin Chinese medicine polysaccharide molecules prepared in Example 1 on the activity of HepG2 cells: The human liver cancer cell line (HepG2) was cultured in a 37°C 5% CO2 incubator with low-glucose DMEM (5.55mM) containing 10% FBS. 5000 cells were inoculated in a 96-well plate per well, and different concentrations of Qihuangyin Chinese medicine polysaccharide molecules (62.5, 125, 250, 500μg / mL, 1, 2, 4mg / mL) were co-cultured with DMEM medium containing 5.55mM and 30mM glucose, respectively. After 24h, the old medium was discarded, and complete medium containing 9% CCK8 (10μL CCK8: 100μL complete medium) was added to each well, incubated at 37°C for 2h, and the culture was terminated. The blank well (no cells were inoculated, containing complete medium and CCK8) was adjusted to zero, and the absorbance of each well was detected at 450nm using an enzyme reader to calculate the activity of the cells. The experimental results are shown in Figure 3 shown.
[0043] Depend on Figure 3 It can be seen that compared with the blank group, with the increase of polysaccharide concentration, the cell growth activity showed a trend of first increasing and then decreasing. When the polysaccharide concentration was 2mg / mL and 4mg / mL, the cell activity was not much different from that of the blank group, indicating that the polysaccharide was relatively safe and high concentration did not affect cell growth.
[0044] 5.2 Effects of Qihuangyin Chinese medicine polysaccharide molecules on the insulin resistance cell model: Glucose and dexamethasone were used to construct the insulin resistance (IR) model of HepG2 cells. After the model was successfully established, the effects on glucose consumption were observed. The glucose consumption of HepG2 cells was most significant at 48 hours after administration of low concentration dexamethasone (30ug / mL).
[0045] Based on the experimental results of 5.1, different concentrations (62.5, 250 μg / mL and 1 mg / mL) of Qihuangyin Chinese medicine molecules and glucose (50 mM) and dexamethasone (30 uM) were used alone or in combination to treat the above insulin resistance model to observe the effects of different concentrations of polysaccharides on cells. The experimental results are as follows: Figure 4 shown.
[0046] As shown in Figure 4, the cell growth was similar when cells were treated with different concentrations of drugs or Qihuangyin Chinese medicine molecules, indicating that the selected drug concentration and polysaccharide concentration did not affect the cell growth activity.
[0047] 5.3 Reactive oxygen species (ROS) detection: Detection principle: 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) itself has no fluorescence and can freely pass through the cell membrane. After entering the cell, it can be hydrolyzed by the esterase in the cell to generate 2',7'-dichlorodihydrofluorescein (DCFH). DCFH cannot penetrate the cell membrane, so the probe can be loaded into the cell. The reactive oxygen in the cell can oxidize the non-fluorescent DCFH to generate fluorescent 2',7'-dichlorofluorescein (DCF). The fluorescence intensity of DCF reflects the level of ROS in the cell.
[0048] Flow cytometry was used to detect intracellular ROS production: 2 × 10 5 cells, with 5.55mM sugar-containing complete medium as blank control (Ctr-L). Based on the experimental results of 5.2, HepG2 cells were treated with dexamethasone + glucose, medium concentration polysaccharide (250μg / mL) + dexamethasone + glucose for 48h, washed twice with PBS after treatment, 1mL DCFH-DA solution was added to each well, and incubated in a 37℃ cell culture incubator for 25min. After incubation, they were washed three times with serum-free DMEM medium, digested with 0.25% (containing EDTA) trypsin, and redispersed with PBS containing 2% FBS into a single cell suspension. The intracellular ROS level was detected by flow cytometry in the FITC fluorescence channel. The results are shown in Figure 5 shown.
[0049] Depend on Figure 5 It can be seen that medium concentration polysaccharides (250 μg / mL) can inhibit the production of ROS (red fluorescence). It can be inferred that polysaccharide molecules may play a role in lowering blood sugar and lipids by inhibiting ROS.
[0050] 5.4 Effects of Qihuangyin Chinese medicine polysaccharide molecular treatment on cell protein expression in insulin resistance cell model: HepG2 cells (7×10 5cells / well) were seeded on 6-well culture plates and cultured overnight, and the cells were treated the same as in 5.3. After treatment, the culture medium was discarded, the remaining culture medium was rinsed off with phosphate-buffered saline (PBS), and the cells were collected and lysed with RIPA solution containing 1% protease inhibitors and 1% phenylmethylsulfonyl fluoride (PMSF). The above operations were all completed on ice; subsequently, the cell lysate was centrifuged at 15,000 rpm for 30 minutes at 4°C, and the supernatant was collected. The total protein content was determined using the BCA protein detection kit. The protein samples were separated using 8-10% SDS / PAGE gel; then, the proteins were transferred to a PVDF membrane, blocked with 5% skim milk for 2 hours, and then incubated with appropriate primary antibodies at 4°C overnight; after washing with TBST buffer, the membrane was incubated with secondary antibodies at room temperature for 2 hours; finally, the protein bands were detected by ECL reagent development. The experimental results are shown in Figure 6 .
[0051] Depend on Figure 6 It can be seen that the expression of p-ERK in the insulin resistance cell model increased, and the polysaccharide molecules inhibited the increase in p-ERK expression, indicating that the polysaccharide molecules of Qihuangyin Chinese medicine improved insulin resistance by inhibiting the production of reactive oxygen species (ROS) and activating the ERK pathway.
[0052] Embodiment 6: The Qihuangyin Chinese medicine polysaccharide molecules extracted in Example 1 of the present invention and the Qihuangyin Chinese medicine crude extract extracted in Comparative Example 1 were used to conduct experiments on the hypoglycemic, hypolipidemic and fatty liver improvement effects on a high-fat and high-fructose diet-induced impaired glucose regulation mouse model.
[0053] 6.1 Test materials Forty-eight male Wistar rats, weighing 200±20 g, were purchased from Hubei Experimental Animal Research Center; atorvastatin calcium tablets (Pfizer Pharmaceuticals Co., Ltd.); metformin tablets (produced by Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.); streptozotocin (Sigma), CypA, insulin, and ADPN ELISA test kits were purchased from Huamei Company, and wolfberry, kudzu root, coix seed, yam, tuckahoe, and turmeric were all purchased from Hubei Tianji Chinese Medicine Pieces Co., Ltd.
[0054] 6.2 Test methods After 2 weeks of adaptive feeding, the rats were randomly divided into 6 groups (normal group, model group, Qihuangyin low-dose group, Qihuangyin high-dose group, metformin group, atorvastatin calcium group). The normal group was fed with ordinary feed throughout the whole process, and the other 5 groups were fed with high-fat feed (D12451 high-fat feed). After 4 weeks, they were fasted for 12 hours but not water, and streptozotocin (STZ) 30 mg / kg was injected intraperitoneally once. After 7 days of fasting for 12 hours but not water, blood was collected from the tail vein, and the blood glucose level of the rats was measured with a Johnson & Johnson blood glucose meter. The rats with fasting blood glucose (FBG) ≥16.7 mmol / L were considered to have successfully established the model. The drug doses of each group were converted according to the human-mouse body surface area method. The high-dose group of Qihuangyin Chinese medicine was given 16.2g / kg by gavage, and the low-dose group was given 8.1g / kg by gavage; the metformin group was given 0.9g / kg by gavage of metformin; the atorvastatin calcium group was given 1.8g / kg by gavage of atorvastatin calcium. The treatment group and the control group were each given the corresponding drug by gavage at 1ml / 100g mass, and the normal group and the model group were given an equal volume of normal saline.
[0055] After continuous gavage for 2 months, the rats were fasted for 12 hours and then anesthetized with 10% chloral hydrate intraperitoneally. Blood was collected from the heart and the rats were killed. The blood lipids (TC, TG, LDL, HDL) and blood glucose (GLU) were detected by automatic biochemical analyzer, and serum CypA, insulin and APDN were detected by Elisa method according to the instructions of the kit. After the blood was collected, the liver, pancreas and kidney were immediately cut out, fixed with 4% formaldehyde, routinely embedded in paraffin, and stained with HE. The pathological changes of the liver, pancreas and kidney were observed under a light microscope. The test results are shown in Tables 2-3 and Figure 7-9 shown.
[0056] 6.3 Test results: 6.3.1 Effects of Qihuangyin Chinese medicine molecules on blood glucose and blood lipids in rats: As shown in Table 2, compared with the normal group, the blood glucose level of rats in the model group was significantly increased ( P <0.01, TC, TG and LDL increased significantly ( P <0.05) and HDL decreased significantly ( P <0.05). Compared with the model group, the blood sugar level in the low-dose Qihuangyin group decreased significantly ( P <0.05), TC, TG and LDL decreased significantly ( P <0.05) and HDL increased significantly ( P <0.05); the blood sugar level in the high-dose Qihuangyin group decreased significantly ( P <0.01), TC, TG and LDL decreased significantly ( P <0.05, P <0.01, P <0.05) and HDL increased significantly ( P<0.05); blood sugar in the metformin group decreased significantly ( P <0.01), and there was no significant difference in blood lipids; TC, TG and LDL in the atorvastatin calcium group decreased significantly ( P <0.05, P <0.01, P <0.05) and HDL increased significantly ( P <0.05), and there was no significant difference in blood sugar. Compared with the atorvastatin calcium group, the TG in the low-dose Qihuangyin group increased significantly ( P <0.05), and there was no significant difference in blood lipids in the high-dose Qihuangyin group. Compared with the metformin group, the blood glucose in the low-dose Qihuangyin group was significantly increased ( P <0.05), and there was no significant difference in blood sugar in the high-dose Qihuangyin group. Compared with the low-dose Qihuangyin group, the blood sugar and TG in the high-dose Qihuangyin group were significantly reduced ( P <0.05).
[0057] It can be seen that different doses of Qihuangyin can significantly reduce the blood sugar and blood lipid levels of diabetic model rats, and increase the level of protective cholesterol HDL; among them, the high-dose group of Qihuangyin has better hypoglycemic and lipid-lowering effects.
[0058] Table 2 Effects of Qihuangyin polysaccharide molecules on blood glucose and blood lipids in rats
[0059] Note: Compared with the normal group, * P <0.05, ** P <0.01; compared with the model group, # P <0.05, ## P <0.01; compared with the metformin group, △ P <0.05; compared with atorvastatin calcium group, ▲ P <0.05; compared with the low-dose group of Qihuangyin, ※ P <0.05.
[0060] 6.3.2 Effects of Qihuangyin Chinese medicine polysaccharide molecules on CypA, Insulin and ADPN in rats: As shown in Table 3, compared with the normal group, CypA and insulin in the model group were significantly increased, while ADPN was significantly decreased (both P <0.01). Compared with the model group, the CypA and insulin levels in the low-dose Qihuangyin group were significantly reduced ( P <0.01, P<0.05), ADPN increased significantly ( P <0.05); CypA and insulin in the high-dose Qihuangyin group were significantly reduced ( P <0.01, P <0.05), ADPN increased significantly ( P <0.01); CypA in atorvastatin calcium group was significantly decreased ( P <0.05), ADPN increased significantly ( P <0.01), and there was no significant difference in insulin; CypA and insulin in the metformin group were significantly reduced (both P <0.01), and there was no significant difference in ADPN. Compared with the metformin group, the ADPN of the high- and low-dose Qihuangyin groups was significantly increased ( P <0.05); compared with the atorvastatin calcium group, the insulin level in the low-dose Qihuangyin group was significantly reduced ( P <0.05), and the CypA and insulin levels in the high-dose Qihuangyin group were significantly reduced (both P <0.05).
[0061] It can be seen that different doses of Qihuangyin can significantly reduce the levels of CypA and insulin, and increase the level of ADPN in diabetic model rats.
[0062] Table 3 Effects of Qihuangyin Chinese medicine polysaccharide molecules on CypA, insulin and ADPN in rats
[0063] Note: Compared with the normal group, ** P <0.01; compared with the model group, # P <0.05, ## P <0.01; compared with the metformin group, △ P <0.05; compared with atorvastatin calcium group, ▲ P <0.05.
[0064] 6.3.3 Effects of Qihuangyin Chinese medicine polysaccharide molecules on rat liver, pancreas and kidneys: like Figure 7As shown, compared with the normal group, Figure b shows that the liver cells in the model group are enlarged, even swollen and rounded, with round vacuoles (fat droplets) of varying sizes in the cytoplasm, the nucleus is squeezed to one side of the cytoplasm and deformed, the liver cells are disordered, the liver sinusoids are narrowed, or even disappear; compared with the model group, it can be seen from Figures e and f that the morphology of liver cells in the low-dose group of Qihuangyin is significantly improved, the nucleus is centered, the cytoplasm is evenly stained, and there are a small number of fat droplets in the cytoplasm. The morphology and structure of liver cells in the high-dose group of Qihuangyin are significantly improved, the liver sinusoids are widened, the liver cords are neatly arranged, and fat droplets are occasionally seen. It shows that the Qihuangyin Chinese medicine polysaccharide molecules of the present invention can alleviate the accumulation of fat droplets in the liver of diabetic rats and have a protective effect on the liver.
[0065] like Figure 8 As shown in Figure b, compared with the normal group, the model group showed hypertrophy and hyperplasia of glomeruli, increased mesangial matrix, and widened mesangial area; inflammatory cell infiltration was obvious, and tubular epithelial cells were obviously edematous or even necrotic and detached. Compared with the model group, it can be seen from Figures e and f that the glomerular volume of the low-dose Qihuangyin group was reduced; the glomerular volume of the high-dose Qihuangyin group was reduced, the degree of inflammatory cell infiltration decreased, and the morphology of tubular epithelial cells was basically normal. It shows that the Qihuangyin Chinese medicine polysaccharide molecules of the present invention can alleviate kidney damage in diabetic rats and have a protective effect on the kidneys.
[0066] like Fig. 9 As shown in Figure b, compared with the normal group, it can be seen from Figure b that the number of pancreatic islets in the model group was significantly reduced, the volume was shrunk, the number of pancreatic islets was significantly reduced, the cell nuclei were of different sizes, and the cells were arranged in a disordered manner; compared with the model group, as shown in Figures e and f, after treatment with various doses of Qihuangyin, the volume of rat islets increased, the morphological structure of pancreatic islet cells was significantly improved, the nuclei of pancreatic islet cells were round and darkly stained, the sizes were basically the same, and the cells were arranged more regularly, indicating that the traditional Chinese medicine molecule Qihuangyin of the present invention has a protective effect on the pancreas.
[0067] Based on the above results, it can be seen that the polysaccharide molecules of Qihuangyin can effectively reduce the blood sugar and blood lipid levels of diabetic model rats, and reduce the damage of liver, kidney and pancreas. Its mechanism of action may be related to its upregulation of ADPN and reduction of CypA and insulin. Qihuangyin has a concise prescription, easy access to medicinal materials, low cost of taking, and definite efficacy, which can give full play to the advantages of simplicity, convenience, cheapness and effectiveness of traditional Chinese medicine; the selected Chinese medicine has a mild nature, which is both a medicinal material and a food material, and is more suitable for long-term use by patients with diabetes and hyperlipidemia.
[0068] Embodiment 7: Clinical efficacy study of Qihuangyin Chinese medicine: 1. Diagnostic criteria 1.1 Diagnostic criteria for diabetes According to the 2017 edition of the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China", the following standards should be met: (1) Typical symptoms of diabetes (polydipsia, polyuria, polyphagia, unexplained weight loss) plus random venous blood glucose (mmol / L) ≥ 11.1; (2) or fasting venous blood glucose (mmol / L) ≥7.0; (3) Or 2-hour venous blood glucose (mmol / L) ≥ 11.1 after a 75-g glucose load. For patients without typical symptoms of diabetes, a recheck on another day is required to confirm that the venous blood glucose (mmol / L) ≥ 11.1.
[0069] Note: Fasting state refers to no food intake for at least 8 hours; random blood glucose refers to blood glucose at any time of the day regardless of the last meal time, and cannot be used to diagnose abnormal fasting blood glucose or abnormal glucose tolerance.
[0070] Diagnostic criteria for type 2 diabetes: Referring to the diabetes etiology classification criteria recommended by the American Diabetes Association (ADA) in July 1997, anyone who meets the diagnostic criteria for diabetes and whose insulin release test results meet one of the following conditions can be diagnosed with type 2 diabetes.
[0071] Insulin release test results: (1) Insulin resistance (IR) with relative insulin (INS) deficiency; (2) significant insulin deficiency with insulin resistance; (3) Those who have been diagnosed with the disease through clinical data do not need to undergo the above tests.
[0072] 1.2 Diagnostic criteria for hyperlipidemia: Diagnosis was made according to the 2016 revised edition of the Guidelines for the Prevention and Treatment of Dyslipidemia in Chinese Adults.
[0073] Table 4 Diagnostic criteria for hyperlipidemia
[0074] Note: Under normal dietary conditions, if fasting blood lipids show any of the above conditions twice within 2 weeks, it can be diagnosed as hyperlipidemia.
[0075] 1.2.1 Inclusion criteria (1) Patients with type II diabetes or hyperlipidemia who meet the diagnostic criteria of Western medicine; (2) fasting venous blood glucose between 7.5-13.8mmol / L; (3) Aged between 30 and 70 years old, regardless of gender; (4) Those with good compliance and able to take medication at the prescribed time and dosage; (5) Patients who expressed informed consent and were willing to participate in this study.
[0076] 1.2.2 Exclusion criteria (1) Those who do not meet the diagnostic criteria and inclusion criteria; (2) Patients with type 1 diabetes or other types of diabetes; (3) Pregnant or lactating women and those who are intolerant or allergic to the drugs in this prescription; (4) Patients with severe acute or chronic complications of diabetes; (5) Patients with abnormal blood sugar and blood lipids due to other diseases; (6) Patients with serious diseases of important organs such as heart, liver, kidney, brain, and mental illness; (7) Patients who are participating in clinical studies of other drugs; (8) Those who are unable to use medications as prescribed and fail to cooperate with the researchers of this project.
[0077] 1.2.3 Suspension and elimination criteria (1) Patients who experience drug allergy and severe adverse reactions during treatment; (2) Patients with severe cardiovascular or cerebrovascular diseases during treatment; (3) Patients who use medication irregularly or stop taking medication on their own during treatment, or are unwilling to cooperate with treatment, fail to have regular follow-up visits, or have ineffective responses to active communication; (4) Patients who wish to become pregnant or have become pregnant during treatment; (5) Patients who want to join other clinical studies during treatment; (6) Patients who take drugs that may affect this study during treatment.
[0078] 1.2.4 Shedding Standard (1) Those who voluntarily withdraw from treatment; (2) Those who cannot continue to participate due to other emergencies; (3) Incomplete clinical data collection makes it impossible to conduct clinical efficacy and safety evaluation; (4) Patients who have lost contact and cannot be tracked or followed up.
[0079] 2. Treatment options: 60 patients with type 2 diabetes combined with hyperlipidemia were selected and randomly divided into a control group and a treatment group, with 30 cases in each group. The control group was given metformin hydrochloride tablets 0.5g TID PO and atorvastatin calcium tablets 20mg qnpo orally; the treatment group was given the Qihuangyin polysaccharide molecular composition prepared in Example 1 on the basis of the treatment of the control group, and the course of treatment was 8 weeks. The blood sugar related indicators (FBG, 2hPG, HbA1c), blood lipid related indicators (TC, TG, HDL-C, LDL-C), total score and single score of TCM syndrome of the two groups of patients before and after treatment were observed and recorded to evaluate the effectiveness of Qihuangyin polysaccharide molecules in treating type 2 diabetes combined with hypertriglyceridemia. The experimental results are shown in Tables 5-7 and Figure 10-17 shown.
[0080] 3. Results and analysis: 3.1 Comparison of blood sugar levels before and after treatment between the control group and the treatment group: The baseline levels of FBG, 2hPG, and HbA1c in the two groups before treatment were consistent (all P >0.05); after treatment, the above indicators in each group were significantly reduced (all P <0.01). The results are shown in Table 5 and Figure 10-12 .
[0081] Table 5 Blood sugar related indicators before and after treatment
[0082] Note: Comparison of data within the same group after treatment and before treatment. ** P <0.01.
[0083] 3.2 Comparison of blood lipids between the control group and the treatment group before and after treatment: The baseline levels of TC, TG, LDL-C and HDL-C in the two groups were consistent before treatment (all P >0.05). After treatment, blood lipid indexes (TC, TG and LDL-C) decreased compared with those before treatment (all P <0.01), the HDL-C in the control group had no significant difference after treatment, while the HDL-C in the treatment group increased significantly after treatment ( P <0.05). The results are shown in Table 6 and Figure 13-16 .
[0084] Table 6 Blood lipid related indicators before and after treatment
[0085] Note: Comparison of data within the same group after treatment and before treatment. * P <0.05, ** P <0.01.
[0086] 3.3 Comparison of total TCM syndrome scores between the control group and the treatment group before and after treatment: The baseline total score of TCM syndromes in the two groups of subjects before treatment was consistent ( P >0.05). After treatment, the total score of TCM syndrome in both the control group and the treatment group decreased significantly compared with that before treatment ( P <0.05, P <0.01), and the decrease in the treatment group was more obvious. The results are shown in Table 7 and Fig.17 .
[0087] Table 7 Comparison of total score of TCM syndrome before and after treatment
[0088] Note: Comparison of data within the same group after treatment and before treatment. * P <0.05, ** P <0.01.
[0089] The above embodiments are only preferred technical solutions of the present invention and should not be regarded as limiting the present invention. The protection scope of the present invention shall be the technical solutions recorded in the claims, including equivalent replacement solutions of the technical features in the technical solutions recorded in the claims. That is, equivalent replacement improvements within this scope are also within the protection scope of the present invention.
Claims
1. A Chinese medicine for Qihuangyin, characterized in that it comprises The components in parts by weight are as follows: 10-30 parts of wolfberry, 10-30 parts of kudzu root, 10-30 parts of coix seed, 10-30 parts of tuckahoe, 10-30 parts of yam, and 10-30 parts of turmeric.
2. The Qihuangyin Chinese medicine according to claim 1, characterized in that: The invention comprises the following components in parts by weight: 20-30 parts of wolfberry, 18-24 parts of kudzu root, 15-19 parts of coix seed, 12-17 parts of tuckahoe, 10-14 parts of yam and 10-15 parts of turmeric.
3. The Qihuangyin Chinese medicine according to claim 1, characterized in that: The invention comprises the following components in parts by weight: 25 parts of wolfberry, 21 parts of kudzu root, 17 parts of coix seed, 15 parts of tuckahoe, 12 parts of yam and 13 parts of turmeric.
4. The Qihuangyin Chinese medicine according to claim 1, characterized in that: The preparation method of the Qihuangyin Chinese medicine comprises the following steps: weighing each component according to the formula, crushing, precipitating with ethanol, deproteinizing, washing, eluting by column chromatography, and dialyzing to obtain the Qihuangyin Chinese medicine polysaccharide molecules with the functions of lowering blood sugar and regulating blood lipids.
5. The Qihuangyin Chinese medicine according to claim 4, characterized in that: The preparation method of Qihuangyin Chinese medicine comprises the following steps: S1. Crushing: Weigh the formula amount of each component of Qihuangyin Chinese medicine, dry it, put it into a grinder, crush it and sieve it to obtain Qihuangyin Chinese medicine powder; S2 alcohol precipitation: add ethanol to the Qihuangyin Chinese medicine powder in step S1 to an alcohol concentration of 75-85%, let stand for 45-50h, centrifuge to obtain a precipitate, dissolve in water, and freeze-dry to obtain a crude extract; S3. Repeated Sevage method to remove protein: add Sevage reagent to the crude extract of step S2, centrifuge and let stand, take the supernatant, repeat 3-5 times, then wash with anhydrous ethanol, acetone and ether in sequence, evaporate the solvent of the obtained precipitate, add water to re-dissolve, pre-freeze at -70°C, and then vacuum freeze-dry to obtain an extract; S4. Separation and purification by DEAE-52 chromatography column: The extract of step S3 is dissolved in ultrapure water, centrifuged, and then loaded onto a DEAE-52 chromatography column for elution, collected step by step, and the absorbance of the eluate is determined by the phenol-sulfuric acid method. An elution curve is drawn and an elution peak is obtained. The eluate of the elution peak is dialyzed and vacuum freeze-dried to obtain the Qihuangyin polysaccharide molecule.
6. The Qihuangyin Chinese medicine according to claim 5, characterized in that: In step S2, ethanol is added to the Qihuangyin Chinese medicine powder in step S1 until the alcohol content is 80%, and the mixture is allowed to stand at 4°C for 48 hours.
7. The Qihuangyin Chinese medicine according to claim 5, characterized in that: In step S3, anhydrous ethanol is centrifuged at 3500 rpm for 15 min, acetone is centrifuged at 3500 rpm for 15 min, and ether is centrifuged at 3500 rpm for 15 min.
8. The Qihuangyin Chinese medicine according to claim 5, characterized in that: In step S4, H2O, 0.2M, 0.4M and 0.6M NaCl solutions are selected as eluents for elution; the elution volume for each concentration is 300ml, the flow rate is 1ml / min, the phenol-sulfuric acid method is used to detect and collect the active components, the eluates are combined according to the elution curve, and after concentration, the dialysis bag with a molecular weight cutoff of 3000Da is dialyzed and desalted for 48 hours, and then the dialysate is concentrated and freeze-dried to obtain the Qihuangyin Chinese medicine polysaccharide molecule.
9. The Qihuangyin Chinese medicine according to claim 5, characterized in that: The infrared detection of the separated and purified material in step S4 shows that at 3435.24 cm -1 The absorption peak at 2926.11 cm is the stretching vibration of OH in sugars. -1 The smaller absorption peak at 1400~1200cm is the stretching vibration of -CH3. -1 The peaks that appear may be CH angle vibrations of sugars. From the above, it can be determined that the sample is a polysaccharide. -1 The absorption peaks near 840 cm indicate that there may be pyranose ring structures in the polysaccharide. -1 The peaks near α indicate that the polysaccharide contains α-configuration, that is, has α-glycosidic bonds.
10. A pharmaceutical composition, characterized in that: The pharmaceutical composition comprises the Qihuangyin Chinese medicine molecule as described in claim 4 and a pharmaceutically acceptable carrier, and the preparation form of the pharmaceutical composition is one of granules, capsules and tablets.
11. Use of the polysaccharide molecules of the Qihuangyin Chinese medicine according to claim 4 in the preparation of medicines or health foods having the effects of lowering blood sugar and blood lipids.
Citation Information
Patent Citations
Cool health-care beer capable of balanced fat-reducing, overall preventing cough and diabetes and beautifying
CN101167992A
Traditional Chinese medicinal cake for preventing and treating type 2 diabetes and preparation method of traditional Chinese medicinal cake
CN104824108A
Process for extracting high-purity puerarin and multiple rare medicinal ingredients from kudzu root
CN107353282A
Application of lycium barbarum polysaccharide in preparation of health care products for preventing hyperglycemia and
CN116327798A
